Bristol Myers Squibb (BMY) to Post Earnings on Thursday

Bristol Myers Squibb (NYSE:BMY) is expected to announce its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to announce earnings of $1.60 per share and revenue of $11.7414 billion for the quarter. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Parties may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, July 30, 2026 at 8:15 AM ET.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The company had revenue of $11.49 billion for the quarter, compared to analysts’ expectations of $10.93 billion. During the same quarter in the prior year, the business earned $1.80 earnings per share. The business’s revenue for the quarter was up 2.6% on a year-over-year basis. On average, analysts expect Bristol Myers Squibb to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Bristol Myers Squibb Stock Performance

Shares of NYSE:BMY opened at $62.56 on Tuesday. The business has a fifty day moving average of $57.59 and a 200-day moving average of $58.12. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. Bristol Myers Squibb has a twelve month low of $42.52 and a twelve month high of $63.44. The firm has a market cap of $127.75 billion, a PE ratio of 17.57, a price-to-earnings-growth ratio of 0.18 and a beta of 0.23.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.0%. Bristol Myers Squibb’s dividend payout ratio is currently 70.79%.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $54.00 target price on shares of Bristol Myers Squibb in a research note on Monday, July 6th. BMO Capital Markets reissued a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday. Bank of America lowered their price target on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a report on Friday, July 10th. Raymond James Financial restated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday. Finally, Guggenheim reaffirmed a “buy” rating and set a $72.00 price objective on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Eight analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Bristol Myers Squibb presently has an average rating of “Hold” and an average target price of $61.25.

Institutional Investors Weigh In On Bristol Myers Squibb

Institutional investors and hedge funds have recently modified their holdings of the business. Empire Financial Management Company LLC boosted its stake in Bristol Myers Squibb by 3.3% in the fourth quarter. Empire Financial Management Company LLC now owns 6,190 shares of the biopharmaceutical company’s stock valued at $334,000 after acquiring an additional 200 shares during the last quarter. GW&K Investment Management LLC raised its position in shares of Bristol Myers Squibb by 16.8% during the 4th quarter. GW&K Investment Management LLC now owns 1,424 shares of the biopharmaceutical company’s stock valued at $77,000 after acquiring an additional 205 shares during the last quarter. Binnacle Investments Inc lifted its stake in shares of Bristol Myers Squibb by 17.0% in the 2nd quarter. Binnacle Investments Inc now owns 1,801 shares of the biopharmaceutical company’s stock valued at $83,000 after purchasing an additional 262 shares during the period. Bank of Jackson Hole Trust boosted its position in shares of Bristol Myers Squibb by 25.5% in the 4th quarter. Bank of Jackson Hole Trust now owns 1,305 shares of the biopharmaceutical company’s stock worth $70,000 after purchasing an additional 265 shares during the last quarter. Finally, E Fund Management Co. Ltd. boosted its position in shares of Bristol Myers Squibb by 2.6% in the 2nd quarter. E Fund Management Co. Ltd. now owns 10,409 shares of the biopharmaceutical company’s stock worth $482,000 after purchasing an additional 267 shares during the last quarter. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.